格隆汇10月14日丨清晰医疗(01406.HK)公告，截至2026年财政年度半年度(自2025年3月31日至2025年9 月30日止6个月)，集团录得收益约8500万港元，较去年同期轻微下降不足3%。由于极端恶劣的天气状 况，集团的香港诊所于七月至九月期间停业或严重中断八天。此外，因某前任董事作出的指控而引致的 负面媒体报道或会对集团近几个月的业务造成不利影响。 公司通过与强生的独家合作引进其新一代屈光手术技术SILK™，进一步巩固在香港眼科市场的技术领 先地位。该技术采用低能量、超精准的飞秒激光脉冲，有效地减轻角膜组织损伤和神经损伤，从而实现 更快的恢复和更好的术後效果。作为香港首家及唯一一家提供SILK™技术的机构，公司计划于2025年 第四季度推广该项技术。 公司股份已于2025年4月15日(星期二)上午九时正起暂停在联交所买卖，并将继续暂停买卖，直至进一 步通知。 诚如公司日期为2025年7月14日的季度更新公告所述，有关公司的持续指控阻碍了主要战略计划的执 行，并损害了业务营运。集团承诺将高效地完成有关调查，稳定营运，以便管理层可重新专注于长期战 略重点。 ...

Core Insights - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the half-year ending in the fiscal year 2026, representing a slight decline of less than 3% compared to the same period last year [1] Group 1: Financial Performance - The company's revenue for the half-year period was approximately HKD 85 million, showing a minor decrease of less than 3% year-on-year [1] - The decline in revenue was attributed to extreme weather conditions that caused the closure or severe disruption of the company's clinics in Hong Kong for eight days during July to September [1] Group 2: Business Challenges - Negative media coverage stemming from allegations made by a former director may have adversely affected the company's business in recent months [1] Group 3: Technological Advancements - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology, SILK [1] - The SILK technology utilizes low-energy, ultra-precise femtosecond laser pulses, effectively reducing corneal tissue and nerve damage, leading to faster recovery and better postoperative outcomes [1] - Clear Medical plans to promote the SILK technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]

Core Viewpoint - Clear Medical (01406) reported a revenue of approximately HKD 85 million for the first half of the fiscal year ending 2026, reflecting a slight decline of less than 3% compared to the same period last year due to adverse weather conditions and negative media coverage [1] Financial Performance - The company achieved revenues of about HKD 85 million, which is a minor decrease of less than 3% year-on-year [1] - The Hong Kong clinics experienced operational disruptions for eight days from July to September due to extreme weather conditions [1] Business Developments - The company has strengthened its technological leadership in the Hong Kong ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce the new generation refractive surgery technology SILK™ [1] - SILK™ technology utilizes low-energy, ultra-precise femtosecond laser pulses to minimize corneal and nerve tissue damage, leading to faster recovery and improved postoperative outcomes [1] - Clear Medical plans to promote the SILK™ technology in the fourth quarter of 2025, being the first and only institution in Hong Kong to offer this technology [1]

2025年10月13日，爱尔眼科（300015）医院集团在优质运营、创新突破、社会贡献等指标中表现优异， 入围《经济观察报》2024—2025年度受尊敬企业。根据经观中国上市公司综合价值评估体系，营业收 入、净利润、总资产、员工薪酬连续三年实现正增长。 ...

华厦眼科首次公开发行股票募集资金总额为305,280.00万元，扣除发行费用(不含增值税)后，募集资金 净额为276,849.25万元。华厦眼科最终募集资金比原计划多198998.64万元。华厦眼科于2022年10月28日 披露的招股说明书显示，该公司原拟募资77,850.61万元，分别用于天津华厦眼科医院项目、区域视光中 心建设项目、现有医院医疗服务能力升级项目、信息化运营管理系统建设项目、补充运营资金项目。 华厦眼科首次公开发行股票的发行费用为28,430.75万元，其中保荐及承销费用为23,201.28万元。 2023年7月4日，华厦眼科披露2022年年度权益分派实施公告。以2022年12月31日的总股本56,000.00万股 为基数，向全体股东每10股派发现金红利人民币2.8元(含税)，共计派发现金红利人民币15,680.00万元； 同时，以资本公积向全体股东每10股转增5股，转增股本前公司总股本为56,000.00万股，转增股本后公 司总股本为84,000.00万股。剩余未分配利润全部结转以后年度分配。 中国经济网北京10月13日讯华厦眼科（301267）(301267.SZ)今日股价下跌，截至收盘 ...

10月10日，普瑞眼科涨0.87%，成交额5025.76万元。两融数据显示，当日普瑞眼科获融资买入额328.71 万元，融资偿还315.19万元，融资净买入13.52万元。截至10月10日，普瑞眼科融资融券余额合计 7078.43万元。 融资方面，普瑞眼科当日融资买入328.71万元。当前融资余额7012.85万元，占流通市值的1.27%，融资 余额低于近一年10%分位水平，处于低位。 截至6月30日，普瑞眼科股东户数1.06万，较上期增加6.24%；人均流通股6647股，较上期减少5.87%。 2025年1月-6月，普瑞眼科实现营业收入14.59亿元，同比增长2.74%；归母净利润1466.75万元，同比减 少66.12%。 分红方面，普瑞眼科A股上市后累计派现7450.74万元。 机构持仓方面，截止2025年6月30日，普瑞眼科十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第三大流通股东，持股259.25万股，相比上期增加69.24万股。圆信永丰聚优A （010469）位居第四大流通股东，持股176.68万股，为新进股东。博时医疗保健混合A（050026）位居 第九大流通股东，持股1 ...

——持续发展消费眼科，推进"内生+外延"战略 报告原因：强调原有的投资评级 买入（维持） | 市场数据： | 2025 年 09 月 30 日 | | --- | --- | | 收盘价（元） | 19.90 | | 一年内最高/最低（元） | 29.40/17.21 | | 市净率 | 2.9 | | 股息率%（分红/股价） | 1.11 | | 流通 A 股市值（百万元） | 6,544 | | 上证指数/深证成指 | 3,882.78/13,526.51 | | 注："股息率"以最近一年已公布分红计算 | | 上 市 公 司 医药生物 2025 年 10 月 08 日 华厦眼科 (301267) | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 6.96 | | 资产负债率% | 25.77 | | 总股本/流通 A 股（百万） | 840/329 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 09-30 10-31 11-30 12-31 01-31 02-28 03-31 04-30 05-31 06- ...

Core Insights - EssilorLuxottica has successfully completed the acquisition of Optegra from MidEuropa, enhancing its presence in the ophthalmology sector [2][3] - Optegra operates over 70 eye hospitals and diagnostic facilities across five key European markets: the UK, Czech Republic, Poland, Slovakia, and the Netherlands [2] - This acquisition aligns with EssilorLuxottica's strategy to expand its med-tech portfolio and improve eye-health solutions for patients [3] Company Overview - The acquisition of Optegra is a significant milestone for EssilorLuxottica, aimed at enhancing personalized and seamless patient journeys in eye care [3] - The transaction has received clearance from all relevant competition authorities, indicating regulatory approval for the acquisition [3]

Core Insights - The article highlights the significant achievements and future plans of Aier Eye Hospital Group in talent development and innovation within the ophthalmology field [1][13] - Aier Eye Hospital has established a strong corporate culture focused on collaboration and shared success, which has contributed to the development of a highly skilled medical team [1][5] Talent Development - Aier Eye Hospital has implemented various targeted talent development programs such as the "优才计划" (Excellent Talent Program), "湘江计划" (Xiangjiang Program), "鲲鹏计划" (Kunpeng Program), and "E计划" (E Program) to cultivate a new generation of medical professionals [5][12] - The hospital has successfully trained 483 full-time graduate students, including 132 doctoral and 351 master's students, through partnerships with 16 universities [12] Clinical Training and Experience - The article features the journey of Dr. Hu Zunxia, who transitioned from a novice to a skilled surgeon through Aier's structured training programs, highlighting the importance of mentorship and hands-on experience [3][5] - Aier Eye Hospital has established an animal eye laboratory in Qinghai to enhance the surgical skills of local ophthalmologists, providing free training to improve healthcare in remote areas [8][9] Social Responsibility and Community Impact - Aier Eye Hospital has made significant contributions to rural revitalization and healthcare accessibility, creating sustainable local medical teams and improving eye care services across 31 provinces in China [9][13] - The hospital's initiatives have been instrumental in addressing the challenges of eye diseases in regions with limited access to medical care, thereby enhancing the overall healthcare landscape [8][9] Research and Innovation - Aier Eye Hospital has published 103 SCI papers and obtained 297 national patents in 2024, demonstrating its commitment to advancing research and clinical applications in ophthalmology [12] - The collaboration with universities to establish research institutions and training bases has fostered a synergistic relationship between academic research and clinical practice [12][13]

Core Insights - The article highlights the successful implantation of the first domestically developed trifocal intraocular lens, named "Leming Vision," at Changsha Aier Eye Hospital, marking a significant advancement in cataract surgery in China [1][3] Group 1: Patient Case Study - A 35-year-old patient, Mr. Xiao, underwent surgery for cataracts, which had severely affected his vision for the past decade [3] - Prior to the surgery, Mr. Xiao's right eye vision was measured at 0.12, with a prescription of -400 degrees, indicating significant visual impairment [3] - Post-surgery, Mr. Xiao achieved excellent vision results, with far, intermediate, and near vision recorded at 1.2, 1.0, and 0.8 respectively on the first day after surgery [3] Group 2: Surgical Procedure - The surgery performed was a "femtosecond laser-assisted cataract phacoemulsification and trifocal intraocular lens implantation," showcasing advanced surgical techniques [3] - The operation was led by Dr. Tang Qiongyan, who has extensive experience with over 30,000 cataract surgeries [1] - The trifocal lens was used for the first time in Hunan Province, indicating a milestone in local medical advancements [1]